Erratum: Chemotherapeutic potential of 2-[Piperidinoethoxyphenyl]-3-Phenyl-2H-Benzo (b)pyran in estrogen receptor- Negative breast cancer cells: Action via prevention of EGFR activation and combined inhibition of PI-3-K/Akt/FOXO and MEK/ERK/AP-1 pathways (PLoS ONE (2013) 8:6: (e66246) DOI: 10.1371/journal.pone.0066246);Chemotherapeutic Potential of 2-[Piperidinoethoxyphenyl]-3-Phenyl-2H-Benzo(b)pyran in Estrogen Receptor- Negative Breast Cancer Cells: Action via Prevention of EGFR Activation and Combined Inhibition of PI-3-K/Akt/FOXO and MEK/Erk/AP-1 Pathways

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Saxena, Ruchi ^a   Chandra, Vishal ^a   Manohar, Murli ^a   Hajela, Kanchan ^a   Debnath, Utsab ^a   Prabhakar, Yenamandra S ^a   Saini, Karan Singh ^a   Konwar, Rituraj ^a   Kumar, Sandeep ^b   Megu, Kaling ^b   Roy, Bal Gangadhar ^c   Dwivedi, Anila ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

^b KING GEORGE'S MEDICAL UNIVERSITY   (India)

^c INSTITUTE OF NUCLEAR MEDICINE AND ALLIED SCIENCES   (India)

Author keywords

[No Author keywords available]

Indexed keywords

2 (PIPERIDINOETHOXYPHENYL) 3 PHENYL 2H BENZO(B)PYRAN; ANTINEOPLASTIC AGENT; CYCLIN D1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN C FOS; PROTEIN C JUN; PROTEIN KINASE B; PROTEIN P27; TRANSCRIPTION FACTOR AP 1; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR FOXO; UNCLASSIFIED DRUG; VASCULOTROPIN; 2 [4 (2 PIPERIDINOETHOXY)PHENYL] 3 PHENYL 2H 1 BENZOPYRAN; BENZOPYRAN DERIVATIVE; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PIPERIDINE DERIVATIVE;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE G1 PHASE; CELL CYCLE S PHASE; CONTROLLED STUDY; DOWN REGULATION; DRUG STRUCTURE; ENZYME INHIBITION; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOLECULAR DOCKING; MOUSE; NONHUMAN; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TRANSCRIPTION INITIATION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; TUMOR CELL LINE;

MUS MUSCULUS;

AGED; ANIMALS; ANTINEOPLASTIC AGENTS; BENZOPYRANS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ENZYME ACTIVATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MIDDLE AGED; MOLECULAR DOCKING SIMULATION; PIPERIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84879241405     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0231282     Document Type: Erratum

References (38)

1. Saxena R, Dwivedi A, (2012) ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective. Med Res Rev 32 (1): 166-215.
2. Jordan VC (1992) The strategic use of antiestrogens to control the development and growth of breast cancer. Cancer 70 (4 Suppl):977-982.
3. Hanahan D, Weinberg RA, (2000) The hallmarks of cancer. Cell 100 (1): 57-70.
4. Rochefort H, Glondu M, Sahla ME, Platet N, Garcia M, (2003) How to target estrogen receptor-negative breast cancer? Endocr Relat Cancer 10 (2): 261-266.
5. Anders C, Carey LA, (2008) Understanding and treating triple-negative breast cancer. Oncology (Williston Park) 22 (11): 1233-1239.
6. Griffiths CL, Olin JL, (2012) Triple negative breast cancer: a brief review of its characteristics and treatment options. J Pharm Pract 25 (3): 319-323.
7. Liu D, He J, Yuan Z, Wang S, Peng R, et al. (2011) EGFR expression correlates with decreased disease-free survival in triple-negative breast cancer: a retrospective analysis based on a tissue microarray. Med Oncol 29 (2): 401-405.
8. Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, et al. (2011) Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol 24 (2): 157-167.
9. Roberts PJ, Der CJ, (2007) Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 26 (22): 3291-3310.
10. Han H, Du B, Pan X, Liu J, Zhao Q, et al. (2010) CADPE inhibits PMA-stimulated gastric carcinoma cell invasion and matrix metalloproteinase-9 expression by FAK/MEK/ERK-mediated AP-1 activation. Mol Cancer Res 8 (11): 1477-1488.
11. Shen Q, Uray IP, Li Y, Zhang Y, Hill J, et al. (2008) Targeting the activator protein 1 transcription factor for the prevention of estrogen receptor-negative mammary tumors. Cancer Prev Res (Phila) 1 (1): 45-55.
12. Biswas DK, Cruz AP, Gansberger E, Pardee AB, (2000) Epidermal growth factor-induced nuclear factor kappa B activation: A major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci U S A 97 (15): 8542-8547.
13. Krol J, Francis RE, Albergaria A, Sunters A, Polychronis A, et al. (2007) The transcription factor FOXO3a is a crucial cellular target of gefitinib (Iressa) in breast cancer cells. Mol Cancer Ther 6 (12 Pt 1): 3169-3179.
14. Zhang YG, Du Q, Fang WG, Jin ML, Tian XX, (2008) Tyrphostin AG1478 suppresses proliferation and invasion of human breast cancer cells. Int J Oncol 33 (3): 595-602.
15. Kim S, Choi JH, Kim JB, Nam SJ, Yang JH, et al. (2008) Berberine suppresses TNF-alpha-induced MMP-9 and cell invasion through inhibition of AP-1 activity in MDA-MB-231 human breast cancer cells. Molecules 13 (12): 2975-2985.
16. Saeed A, Sharma AP, Durani N, Jain R, Durani S, et al. (1990) Structure-activity relationship of antiestrogens. Studies on 2,3-diaryl-1-benzopyrans. J Med Chem 33 (12): 3210-3216.
17. United States Patent no. 5254,568; Inventors: RS Kapil, S. durani, JD Dhar, BS Setty; Title: Benzopyrans as anti-estrogenic agents.
18. Sharma AP, Saeed A, Durani S, Kapil RS, (1990) Structure-activity relationship of antiestrogens. Effect of the side chain and its position on the activity of 2,3-diaryl-2H-1-benzopyrans. J Med Chem 33: 3216-3222.
19. Dhar JD, Setty BS, Durani S, Kapil RS, (1991) Biological profile of 2-[4-(2-N-piperidinoethoxy) phenyl]-3-phenyl(2H)benzo(b) pyran- a potent anti-implantation agent in rat. Contraception 44: 461-72.
20. Sreenivasulu S, Singh MM, Dwivedi A, Setty BS, Kamboj VP, (1992) CDRI-85/287, a novel antiestrogen and antiimplantation agent: biological profile and interaction with the estrogen receptors in immature rat uterus. Contraception 45: 81-92.
21. Dwivedi A, Bansode FW, Setty BS, Dhar JD, (1999) Endometrial steroid receptors during decidualization in rhesus monkey (Macaca mulatta); their modulation by anti-oestrogen CDRI-85/287. Hum Reprod 14: 1090-1095.
22. Fatima I, Chandra V, Saxena R, Manohar M, Sanghani Y, et al. (2012) A 2,3-Diaryl-2H-1-benzopyran derivatives interfere with classical and non-classical estrogen receptor signaling pathways, inhibit Akt activation and induce apoptosis in human endometrial cancer cells. Mol Cell Endocrinol 348 (1): 198-210.
23. Gupta A, Mandal SK, Leblanc B, Descôteaux V, Asselin E, et al. (2008) Synthesis and cytotoxic activity of benzopyran-based platinum(II) complexes. Bio Med Chem Lett 18: 3982-3987.
24. Bresch GJ, Wolberg WH, Gilchrist KW, Voelkel JG, Gould MN, (1983) A comparison of methods for the production of monodispersed cell suspensions from human primary breast carcinomas. Breast Cancer Res Treat 3 (1): 15-22.
25. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, et al. (2009) AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility. J Comput Chem 30 (16): 2785-2791.
26. SYBYL, version 7.3 (2006) Tripos Associates, St. Louis, MO, USA.
27. Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, et al. (2004) A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res 64 (18): 6652-6659.
28. Seeliger D, de Groot BL, (2010) Ligand docking and binding site analysis with PyMOL and Autodock/Vina. J Comput Aided Mol Des 24 (5): 417-422.
29. MOE: The Molecular Operating Environment from Chemical Computing Group Inc, 1255 University St, Suite 1600, Montreal, Quebec, Canada H3B 3X3 (2012) Journal of Computer-Aided Molecular Design 26(6): 775-786 (last issue). Available: https://www.chemcomp.com/MOE-Structure_Based_Design.html.
30. Blesson CS, Awasthi S, Kharkwal G, Daverey A, Dwivedi A, (2006) Modulation of estrogen receptor transactivation and estrogen-induced gene expression by ormeloxifene-a triphenylethylene derivative. Steroids 71 (11-12): 993-1000.
31. Xu YZ, Zheng RL, Zhou Y, Peng F, Lin HJ, et al. (2011) Small molecular anticancer agent SKLB703 induces apoptosis in human hepatocellular carcinoma cells via the mitochondrial apoptotic pathway in vitro and inhibits tumor growth in vivo. Cancer Lett 313 (1): 44-53.
32. Meloche S, Pouyssegur J, (2007) The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 26 (22): 3227-3239.
33. Dolcet X, Llobet D, Pallares J, Matias-Guiu X, (2005) NF-κB in development and progression of human cancer. Virchows Arch 446 (5): 475-482.
34. Hu MC, Lee DF, Xia W, Golfman LS, Ou-Yang F, et al. (2004) IkappaB kinase promotes tumorigenesis through inhibition of forkhead FOXO3a. Cell 117 (2): 225-237.
35. Ellerbroek SM, Halbleib JM, Benavidez M, Warmka JK, Wattenberg EV, et al. (2001) Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association. Cancer Res 61 (5): 1855-1861.
36. Ling H, Zhang Y, Ng KY, Chew EH, (2011) Pachymic acid impairs breast cancer cell invasion by suppressing nuclear factor-kappaB-dependent matrix metalloproteinase-9 expression. Breast Cancer Res Treat 126 (3): 609-620.
37. Chen PS, Wang MY, Wu SN, Su JL, Hong CC, et al. (2007) CTGF enhances the motility of breast cancer cells via an integrin-alphavbeta3-ERK1/2-dependent S100A4-upregulated pathway. J Cell Sci 120 (Pt 12): 2053-2065.
38. Shimo T, Kubota S, Yoshioka N, Ibaragi S, Isowa S, et al. (2006) Pathogenic role of connective tissue growth factor (CTGF/CCN2) in osteolytic metastasis of breast cancer. J Bone Miner Res 21 (7): 1045-1059.